MedTrace Logo

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT02930954 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-10-13

No results posted yet for this study

Summary

This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of combination of gefitinib and doublet chemotherapy or antiangiogenesis in advanced non-small cell lung cancer patients with EGFR activating mutation, accompanied with Bim deletion or low activating EGFR mutation abundance.

Conditions

  • Non-small-cell Lung Cancer

Interventions

DRUG

Gefitinib

Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.

DRUG

pemetrexed or gemcitabine plus carboplatin,

doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks

DRUG

bevacizumab

bevacizumab 7.5mg/kg intravenously per 3 weeks

Sponsors & Collaborators

  • Caicun Zhou

    lead OTHER

Principal Investigators

  • Caicun Zhou, MD,PhD · Shanghai Pulmonary Hospital, Tongji University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02930954 on ClinicalTrials.gov